Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
暂无分享,去创建一个
Aung Ko Win | J. Potter | G. Giles | J. Hopper | S. Thibodeau | L. Le Marchand | B. Leggett | G. Casey | J. Baron | P. Newcomb | M. Jenkins | D. Ahnen | S. Gallinger | Joanne P Young | N. Lindor | C. Rosty | D. Buchanan | M. Clendenning | R. Haile | I. Winship | F. Macrae | D. Ait Ouakrim | S. G. Dashti | R. Chau | M. Jenkins
[1] N. Cook,et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women , 2014, Heart.
[2] Y. Hirooka,et al. Risk factors of symptomatic NSAID‐induced small intestinal injury and diaphragm disease , 2014, Alimentary pharmacology & therapeutics.
[3] N. Cook,et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] S. Kudo,et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial , 2014, Gut.
[5] X. Ye,et al. Dose–Risk and Duration–Risk Relationships between Aspirin and Colorectal Cancer: A Meta-Analysis of Published Cohort Studies , 2013, PloS one.
[6] P. Møller,et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.
[7] D. Bishop,et al. Edinburgh Research Explorer Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer , 2022 .
[8] P. Moayyedi,et al. Does aspirin really reduce the risk of colon cancer? , 2012, The Lancet.
[9] Aung Ko Win,et al. Substantial unexplained variation in cancer risks for MLH1 and MSH2 mutation carriers , 2012, Human mutation.
[10] Aung Ko Win,et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Rodney J Scott,et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.
[12] F. Couch,et al. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. , 2011, Cancer research.
[13] D. Bishop,et al. A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis , 2011, Cancer Prevention Research.
[14] Aung Ko Win,et al. Body Mass Index in Early Adulthood and Endometrial Cancer Risk for Mismatch Repair Gene Mutation Carriers , 2011, Obstetrics and gynecology.
[15] Emily J. Greenspan,et al. Ibuprofen Inhibits Activation of Nuclear β-Catenin in Human Colon Adenomas and Induces the Phosphorylation of GSK-3β , 2011, Cancer Prevention Research.
[16] A. de la Chapelle,et al. The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means? , 2011, Cancer Prevention Research.
[17] A. Algra,et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.
[18] Brendan Delaney,et al. Diagnosis and management of Barrett’s oesophagus , 2010, BMJ : British Medical Journal.
[19] R. Steele,et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) , 2010, Gut.
[20] Samy Suissa,et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.
[21] J. Potter,et al. Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center , 2010, Clinical Cancer Research.
[22] H T Lynch,et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.
[23] M. Thun,et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.
[24] J. Baron,et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.
[25] J. Potter,et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. , 2008, Gastroenterology.
[26] P. Maisonneuve,et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.
[27] B. Levin,et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.
[28] Dieter Niederacher,et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2008, American journal of human genetics.
[29] David W. Hosmer,et al. Applied Survival Analysis: Regression Modeling of Time-to-Event Data , 2008 .
[30] Samy Suissa,et al. Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.
[31] John D Potter,et al. Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.
[32] Shuji Ogino,et al. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.
[33] P. Rothwell,et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.
[34] G. Petersen,et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. , 2006, JAMA.
[35] J. Chang-Claude,et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] G. Giles,et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[37] John L Hopper,et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Chang-Claude,et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high‐risk susceptibility genes , 2005, Genetic epidemiology.
[39] Z. Halpern,et al. Rofecoxib Reduces Polyp Recurrence in Familial Polyposis , 2003, Digestive Diseases and Sciences.
[40] Douglas G Altman,et al. Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.
[41] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[42] W. Zoller,et al. [Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer]. , 2001, Zeitschrift fur Gastroenterologie.
[43] J. Marx. Anti-Inflammatories Inhibit Cancer Growth--But How? , 2001, Science.
[44] L. Aaltonen,et al. Population carrier frequency of hMSH2 and hMLH1 mutations , 2000, British Journal of Cancer.
[45] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[46] R L Williams,et al. A Note on Robust Variance Estimation for Cluster‐Correlated Data , 2000, Biometrics.
[47] S. Shapiro,et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption , 1999, American Journal of Gastroenterology.
[48] K. Kinzler,et al. PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.
[49] K. Kinzler,et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[50] P. Remington,et al. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[51] R. DuBois,et al. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.
[52] K. Schmid,et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment , 1995, Diseases of the colon and rectum.
[53] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[54] S. Piantadosi,et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.
[55] L F Watson,et al. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.
[56] A. Price,et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. , 1988, Gastroenterology.
[57] P. Laird,et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. , 2011, The Journal of molecular diagnostics : JMD.
[58] F. Couch,et al. Modification of BRCA 1-Associated Breast and Ovarian Cancer Risk by BRCA 1-Interacting Genes , 2011 .
[59] Feng Yang,et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2009, The New England journal of medicine.
[60] J. Meyerhardt,et al. Aspirin dose and duration of use and risk of colorectal cancer in men. , 2008, Gastroenterology.
[61] J. Hopper. Application of genetics to the prevention of colorectal cancer. , 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[62] J. Marx. Cancer research. Anti-inflammatories inhibit cancer growth--but how? , 2001, Science.
[63] K. Kinzler,et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. , 1999, Cell.
[64] L. Aaltonen,et al. A novel approach to estimate the proportion of hereditary nonpolyposis colorectal cancer of total colorectal cancer burden. , 1994, Cancer detection and prevention.
[65] W. Rogers. Regression standard errors in clustered samples , 1994 .
[66] T. Westfall,et al. ALTERATIONS IN THE , 1985 .